Showing results (161-170 of 362) with videos related to

Sort By:
Pageof 37
Journal of the American Heart Association|September 7, 2020
Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME TrialSimke W Waijer, Di Xie, Silvio E Inzucchi, et al.
The Journal of Clinical Endocrinology and Metabolism|December 10, 2016
Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical TrialCatherine M Viscoli, Silvio E Inzucchi, Lawrence H Young, et al.
Diabetes Care|September 24, 2016
Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013Kasia J Lipska, Xiaoxi Yao, Jeph Herrin, et al.
Circulation|December 28, 2018
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME TrialDavid Fitchett, Silvio E Inzucchi, Christopher P Cannon, et al.
Sleep & Breathing = Schlaf & Atmung|May 20, 2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trialBrian S Wojeck, Silvio E Inzucchi, Ian J Neeland, et al.
JAMA Internal Medicine|May 20, 2014
National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011Kasia J Lipska, Joseph S Ross, Yun Wang, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trialMuthiah Vaduganathan, Silvio E Inzucchi, Naveed Sattar, et al.
Diabetes, Obesity & Metabolism|April 1, 2020
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trialSubodh Verma, Abhinav Sharma, Bernard Zinman, et al.
Diabetes Care|April 24, 2010
The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapyJulio Rosenstock, Salomon Banarer, Vivian A Fonseca, et al.
Diabetes Research and Clinical Practice|March 22, 2022
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary diseaseStefan D Anker, Leif-Erik Sander, David H Fitchett, et al.
Pageof 37